Tirzepatida

Precios por volumen

Precio por envase (10 viales). El descuento se aplica únicamente a este compuesto; no se admiten combinaciones.

Tirzepatide — GLP-1R / GIPR Dual Agonist (“Twincretin”)

Tirzepatide is a synthetic 39-amino acid peptide engineered to simultaneously activate two key incretin hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Its dual-receptor profile positions it between the well-established selectivity of semaglutide and the triple-agonist complexity of retatrutide, making it one of the most pharmacologically distinctive compounds available for metabolic research. Structurally based on the native GIP sequence with a C20 fatty diacid moiety enabling albumin binding, tirzepatide achieves a half-life consistent with once-weekly dosing protocols.

Why Dual Incretin Agonism Matters

What makes tirzepatide particularly notable in research is not just that it hits two receptors — it’s how it hits them. Tirzepatide is an imbalanced agonist: it binds the GIP receptor with affinity comparable to native GIP, while engaging the GLP-1 receptor with notably weaker affinity. This pharmacological asymmetry is thought to be a feature, not a limitation — full GIPR engagement appears to potentiate GLP-1R signaling in ways that exceed what selective GLP-1R agonism alone can achieve, while keeping GI tolerability more manageable at escalating doses.

The synergistic interaction between GIP and GLP-1 receptor activation is a primary subject of active research — co-activation produces insulin and glucagonostatic responses that exceed what either pathway delivers independently.

Aplicaciones de investigación

Tirzepatide is used in studies examining:

• Dual incretin synergy and its contribution to metabolic outcomes beyond GLP-1R agonism alone
• Comparative efficacy against selective GLP-1R agonists (semaglutide) and triple agonists (retatrutide)
• Beta-cell function preservation and insulin sensitivity improvement in metabolic models
• Body composition and adipose tissue dynamics under dual receptor activation
• Hepatic lipid accumulation and MASH/MASLD pathway research
• Dose-response relationships in imbalanced receptor engagement protocols
• GIP receptor biology and its role in energy homeostasis — historically understudied, now of significant interest

Especificaciones

Reconstitución

Tirzepatide arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total en mg ÷ Volumen añadido (mL) = Concentración (mg/mL)

Ejemplo: vial de 10 mg + 2 ml de agua destilada = solución de 5 mg/ml

El péptido reconstituido debe conservarse a una temperatura de entre 2 y 8 °C y utilizarse en un plazo de 28 a 30 días.

Notas sobre el protocolo

Due to its imbalanced dual-receptor activity and long half-life, tirzepatide protocols employ gradual dose escalation to characterize the individual receptor contributions at each stage and allow for observation of GI-related receptor adaptation.

Esquema típico de titulación:

• Starting dose: 0.5–1mg per administration
• Escalation: Increase by 0.5–1mg every 2–4 weeks as tolerated
• Frecuencia: una vez a la semana (en consonancia con su perfil de semivida prolongada)
• Duración del estudio: entre 8 y 16 semanas para los parámetros de composición corporal y metabólicos

Efectos observados con frecuencia en modelos de investigación:

• GI-related (receptor-mediated, typically transient): Nausea, vomiting, diarrhea, constipation, reduced appetite, early satiety — dose-dependent in incidence and generally most pronounced during escalation phases
• Aspectos metabólicos: reducción de la ingesta calórica, alteraciones del equilibrio hídrico y consideraciones electrolíticas con dosis elevadas prolongadas
• Otros: irritación en el lugar de la inyección, dolor de cabeza, mareos leves en los intervalos de aumento de la dosis

Pilas de investigación

Tirzepatide is commonly paired in research settings with:

• Semaglutide — Semaglutide is a mono-selective GLP-1 receptor agonist; researchers pair with Tirzepatide’s dual GLP-1/GIP agonism to isolate the incremental contribution of GIP receptor co-engagement to outcomes observed with GLP-1 signaling alone.
• CJC-1295 No DAC / Ipamorelin — CJC-1295 No DAC and Ipamorelin stimulate GH secretion via GHRH and ghrelin receptors; pairing with Tirzepatide’s incretin receptor activity allows researchers to study interactions between the GH/IGF-1 axis and dual GLP-1/GIP receptor signaling in metabolic research models.
• MOTS-c — MOTS-c activates AMPK to enhance peripheral insulin sensitivity and mitochondrial efficiency; combining with Tirzepatide’s GLP-1/GIP-mediated pancreatic and central signaling provides a model for studying convergent central and cellular mechanisms of metabolic regulation.

Garantía de pureza

Cada lote tiene una pureza ≥99 %. Si sometes tu compuesto a un análisis independiente y los resultados no coinciden, envíanos el certificado de análisis (COA) y te concederemos un vale de compra sin hacerte preguntas.